A national retrospective study led by researchers at MD Anderson Cancer Center found no association between intensity of post-treatment surveillance and detection of recurrence or overall survival in patients with stage I, II or III colorectal cancer. Published in the Journal of the American Medical Association, the study is the largest of surveillance intensity in CRC ever conducted.
FDA has alerted health care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1.
Genentech announced positive results from the phase III IMpower150 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel for the first-line treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.
In a phase III trial of Lonsurf (trifluridine and tipiracil) plus best supportive care versus placebo plus BSC in patients with previously treated metastatic gastric cancer, the Lonsurf-containing arm met the primary endpoint of prolonged overall survival.
According to the Oncology Nursing Society's new position statement, “Role of the Oncology Nurse Navigator Throughout the Cancer Trajectory,” oncology nurse navigators are crucial to the successful outcomes of patients with cancer. Through clinical expertise, care coordination skills, and leadership abilities, ONNs are able to guide their patients during the cancer trajectory.
Merck said the pivotal phase III KEYNOTE-407 trial investigating Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as first line treatment for metastatic squamous non-small cell lung cancer met a pre-specified secondary endpoint of overall response rate in an early cohort of participants at an interim analysis.
TESARO Inc. said the QUADRA study of Zejula treatment in heavily pre-treated patients with ovarian cancer achieved the pre-specified primary endpoint and demonstrated Zejula monotherapy activity in a biomarker-selected patient population.
Merck announced results from KEYNOTE-189, a pivotal phase III trial evaluating Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
